The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome

Central South University

Status: Unknown

Conditions: Schizophrenia; Metabolic Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT02093858

RRW

Details and patient eligibility

About

Almost all of antipsychotics can induce metabolic syndrome,Genetic factors play a key role in the development of metabolic syndrome,TCF7L2 and SLC30A8 are strongestly correlated with metabolic syndrome.Moreover,Antipsychotics have an effect on the expression of TCF7L2 and SLC30A8 genes.It indicates the variations of TCF7L2 and SLC30A8 play an important part in the development of antipsychotics-induced metabolic syndrome.

Full description

• In this study, we will determine the effect of olanzapine on the expression of TCF7L2 and SLC30A8.
• The relationship of the polymorphism of TCF7L2 and SLC30A8 with antipsychotic-induced metabolic syndrome in schizophrenia patients.

Enrollment: 212 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of first episode schizophrenia
• Must be able to swallow tablets
• Take only one antipsychotics

Exclusion criteria

• liver or renal or cardiovascular diseases
• pregnant or lactating women
• drug and alcohol dependence

Trial design

212 participants in 1 patient group

olanzapine

Description:

15-25mg/day for 24 weeks